Article Sidebar

Download
PDF
Statistic
Read Counter : 266 Download : 234

Main Article Content

Abstract

Histopathological examination of products of conception from miscarriages is part of routine clinical practice. The extent of additional clinically relevant information provided by this investigation in the setting of recurrent spontaneous abortion remains uncertain. The included studies indicated that such examination identify hydatid form moles, villous dysmorphic features suggesting fetal aneuploidy, chronic histiocytic intervillositis (CHI) and massive per villous fibrin deposition and impaired trophoblast invasion. However, in most cases, morphological assessment cannot reliably determine the cause of the miscarriage or distinguish recurrent from sporadic miscarriage. Studies reporting on the use of additional immunohistochemically methods do not currently provide additional clinically useful diagnostic or prognostic information. Routine histological examination of products of conception in the setting of recurrent spontaneous abortion can provide important clinical information in a minority of cases.

Keywords

Abortion Incomplete abortion Placenta Histopathology Miscarriage

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite
Al-Hakeem, A. H. ., Meri, M. A., & Aldujaili, H. H. (2022). Placenta Accreta Spectrum: A Review of Morphological, Histopathological of the Placenta in first-trimester Spontaneous Abortions. Medical Science Journal for Advance Research, 3(1), 1–11. https://doi.org/10.46966/msjar.v3i1.33
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Albrektsen G., Heuch I., Hansen S and Kvåle G: Breast cancer risk by age at birth, time since birth and time intervals between births: exploring interaction effects. Br J Cancer 2005, 92:167-175.
  2. Bailit, J.L., Grobman W.A., Riceetal. M.M.,“Morbidlyadherent placenta treatments and outcomes,” Obstetrics & Gynecology, vol. 125, no. 3, pp. 683–689, 2015.
  3. Ball E, Robson S, Ayis S, Lyall F and Bulmer J (2006) Early embryonic demise: no evidence of abnormal spiral artery transformation or trophoblast invasion. J Pathol 208,528–534.
  4. Baron J, Vecchia CL, Levi F. (1990): The anti-estrogenic effect of cigarette smoking in women. American Journal of Obsterics and Gynecology. 162, 502-514.
  5. Boiesen P, Bendahl PO, Anagnostaki L, Domanski H, Holm E, Idvall I, Johansson S, Ljungberg O, Ringberg A, Ostberg G, Fernö M: Histologic grading in breast cancer: reproducibility between seven pathologic departments. In Acta Oncol. Volume 39. South Sweden Breast Cancer Group; 2000:(1):41-5.
  6. Breeze C. “Early pregnancy bleeding”. Australian Family Practitioner 45.5 (2016): 283-286. 2.
  7. Brien J.M. Barton J.R., and Donaldson E.S.,“Themanagement of placenta percreta: conservative and operative strategies,” American Journal of Obstetrics & Gynecology, vol. 175, no. 6, pp. 1632–1638, 1996.
  8. Bulla R, de Guarrini F and Pausa M (1999) Inhibition of trophoblast adhesion to endothelial cells by the sera of women with recurrent spontaneous abortions. Am J Reprod Immunol 42,116–123.
  9. Burton G. Jauniaux J. , E. and Bhide A. “Chapter 2 Pathophysiology of accreta,” in Placenta Accreta Syndrome, Silver, Taylor and Francis, 2017.
  10. Chuong E., “Evolutionary perspectives into placental biology and disease,” Applied & Translational Genomics, vol. 2, pp. 64–69, 2013.
  11. Collins S., Burton G. J. and Jauniaux E. “Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging,” American Journal of Obstetrics & Gynecology, vol. 218, no. 1, pp. 75–87, 2018.
  12. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. (Eds). (2007): Cancer incidence in Five Continents. Lyon: Vol. IX IARC Scientific Publications, No. 160.
  13. Dannheim K., Shainker S.A., and Hecht J.L., “Hysterectomy for placenta accreta; methods for gross and microscopic pathology examination,” Archives of Gynecology and Obstetrics, vol. 293, no. 5, pp. 951–958, 2016.
  14. Donnelly K and R Thompson. “Medical versus surgical methods of early abortion: protocol for a systematic review and environmental scan of patient decision aids British medical journal 5.7 (2015). 1-8.
  15. Easton DF, Pooley KA, Dunning AM, pharaoh PDP, Thompson D, Ballinger D, et al. (2007): Genome wide associated study identifies novel breast cancer susceptibility loci. Nature. 447, 1087-1094.
  16. Egevad.L, “Handling and reporting of radical prostatectomy specimens,” Diagnostic Histopathology, vol. 60, no. 1, pp. 118– 124, 2012.
  17. Elston CW, Ellis IO: Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
  18. Emmer PM, Steegers EA and Kerstens HM (2002) Altered phenotype of HLA-G expressing trophoblast and decidual natural killer cells in pathological pregnancies. Hum Reprod 17,1072–1080.
  19. Ernst L.M., Linn R.L., Minturn L., and Miller E.S., “Placental pathologic associations with morbidly adherent placenta: potential insights into pathogenesis,” Pediatric and Developmental Pathology, vol. 20, no. 5, pp. 387–393, 2017.
  20. Fackenthal JD and Olopade O. (2007): Breast cancer risk associates with BRCA1 and BRCA2 mutations in diverse populations. Nat Rev Cancer. 7, 937-947.
  21. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. (2010): Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer. 127, 2893– 2917.
  22. Fisher RA, Hodges MD and Newlands ES (2004) Familial recurrent hydatidiform mole: a review. J Reprod Med 49,595–601.
  23. Fitzpatrick K. E., Sellers S., Spark P., Kurinczuk J. J., Brocklehurst P. , and M. Knight, “The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 121, no. 1, pp. 62– 71, 2014.
  24. Gaillard DA, Paradis P, Lalleman AV, et al. Spontaneous abortions during the second trimester of gestation.Arch Pathol Lab Med 1993;117:1022–6.
  25. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. (Eds). (2007): Global Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society. Page 1-3.
  26. Garner C, Mathews H, Burka L. (2000): Phenolphthalein metabolite inhibits catechol- O-methyl transferase-mediated metabolism of catechol estrogens: a possible mechanism for carcinogenicity. Toxicology and Applied Pharmacology, 2000. 162, 124-131.
  27. Gerdts C. “Measuring Unsafe Abortion-Related Mortality: A Systematic Review of the Existing Methods”. PLoS ONE 8.1 (2013).
  28. Giakoumelou S. “The role of infection in miscarriage”. Human Reproduction Update 22.1 (2016): 116-133.5.
  29. Ginsburg OM and Love RR. (2011): Breast Cancer: a neglected disease for the majority of affected women worldwide. Breast J. 17, 289-295.
  30. Higgins M., Monteith C., Foley M., and ’Herlihy C.O., “Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section,” European Journal of Obstetrics & Gynecology, and Reproductive Biology, vol. 171, no. 1, pp. 54–56, 2013.
  31. Horn-Ross PL, Lee M, John EM, Koo J. (2000): Sources of phytoestrogen exposure among non-Asian women in California. Cancer Causes and Control.11, 299-301.
  32. Irving. C and. Hertig A. T, “A study of placenta accreta,” Surgery, Gynecology & Obstetrics, vol. 38, no. 6, pp. 1088– 1200, 1937.
  33. Jacques SM and Qureshi F (1993) Chronic intervillositis of the placenta. Arch Pathol Lab Med 117,1032–1035.
  34. Jauniaux E and Burton GJ (2005) Pathophysiology of histological changes in early pregnancy loss. Placenta 26,114–123.
  35. Jauniaux E, Chantraine F, Silver R.M., Langh J, off-Roos, and for the FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel, “FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology,” International Journal of Gynecology & Obstetrics, vol. 140, no. 3, pp. 265–273, 2018.
  36. John E and Kelsey J. (1993): Radiation and other environmental exposures and breast cancer. Epidemiology Reviews, 1993. 15,157-162.
  37. Jungheim E. “Obesity and Reproductive Function”. Obstetrics and Gynecology of Clinical North America 39.4 (2012): 479-493.
  38. Kanavos P. (2006): The rising burden of cancer in the developing world. Ann Oncol. 17, 15-23.
  39. Katzman PJ and Genest DR (2002) Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatr Dev Pathol 5,159–164.
  40. Khong TY, Liddell HS and Robertson WB (1987) Defective haemochorial placentation as a cause of miscarriage: a preliminary study. Br J Obstet Gynaecol 94,649–655.
  41. Knight M., Nair M., Tuffnell D. et al., Saving Lives, Improving Mothers’ Care Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013
  42. Kristensen VN et al. (2000): Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 19,1329-1333.
  43. Kuper H et al. (2000): Alcohol and breast cancer risk: the alcoholism paradox. British Journal of Cancer. 83, 949-951.
  44. Larsen E.“New insights into mechanisms behind miscarriage”. BMC Medicine 11 (2013): 154-164.
  45. Laudico AV, Fernandez AM, Lim FG, et al. (2007): Immunohistochemically assay of hormone receptors in breast cancer at the Philippine General Hospital: Importance of early fixation of specimen. Philipp Jsurg Spec. 62,123-127.
  46. Lawrence J.B., Oxvig, C. Overgaard M.T. et al., “The insulinlike growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancyassociated plasma protein-A,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 6, pp. 3149–3153, 1999.
  47. Li CL, Anderson BO, Daling JR, et al. (2003): Trends in incidence rates of invasive lobular and ductal breast carcinoma. J Am Med Assoc. 289, 1421-1424.
  48. Li CL, Malone KE and Daling JR (2002): Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidermal Biomarkers Prev. 11, 601-607.
  49. Michel MZ, Khong TY, Clark DA and Beard RW (1990) A morphological and immunological study of human placental bed biopsies in miscarriage. Br J Obstet Gynaecol 97,984–988.
  50. Miller E.S, Linn R.L. , and Ernst L.M. “Does the presence of placental basal plate myometrium fibres increase the risk of subsequent morbidly adherent placenta: a case–control study,” BJOG: An International Journal of Obstetrics & Gynecology, vol. 123, no. 13, pp. 2140–2145, 2016.
  51. Mitruen K, and Hirvonen A. (2003): Molecular epidemiology of sporadic breast cancer: The role of polymorphic genes involved estrogen biosynthesis and metabolism. Mutation .544, 9-41.
  52. Oztas E., Ozler S., Caglar A.T., and Yucel A., “Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy,” The Kaohsiung Journal of Medical Sciences, vol. 32, pp. 579– 585, 2016.
  53. Parkin DM, Bray F, Ferlay J, Pisani P. (2005): Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
  54. Parkin DM and Fernandez LM. (2006): Use of statistics to assess the global burden of breast cancer. Breast J. 12, S70-S80.
  55. Pineles B. “Systematic Review and Meta-Analysis of Miscarriage and Maternal Exposure to Tobacco Smoke During Pregnancy”. American Journal of Epidemiology 179.7 (2014): 807-823.
  56. Porter P.(2008): Westernizing women’s risks? Breast cancer in low-income countries. New Eng. J med. 358, 213-216.
  57. Ramasamy R. “Male biological clock: a critical analysis of advanced paternal age”. Fertility and Sterility 103.6 (2016): 14021406
  58. Rushton DI (1978) Simplified classification of spontaneous abortions. J Med Genet 15,1–9.
  59. Samaratunga. H., R. Montironi, L. True et al., “International society of urological pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1: specimen handling,” Modern Pathology, vol. 24, no. 1, pp. 6–15, 2011.
  60. Say L., et al. “Global causes of maternal death: a WHO systematic analysis”. Lancet Global Health 2.6 (2014): e323-e33.7 “Global causes of maternal death: a WHO systematic analysis”. Lancet Global Health 2.6 (2014): e323-e33.7
  61. Sebire NJ, Fox H, Backos M, Rai R, Paterson C and Regan L (2002) Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod 17,1067–1071.
  62. Silver R.M. and Barbour K.D., “Placenta accreta spectrum: accreta, increta, and percreta,” Obstetrics and Gynecology Clinics of North America, vol. 42, no. 2, pp. 381–402, 2015.
  63. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20(17):3628-36.
  64. Thoresen S, Albrektsen G, Heuch I, Kvåle G: Family history of breast cancer and short-term effects of childbirths on breast cancer risk. Into Cancer 2006, 119:1468-1474.
  65. Tran D and Lawson J. (2004): Rates of estrogen receptor-alpha expression are no different in low-risk (Vietnam) and high-risk (Austarlian) breast cancer. Appl Immunohistochem Mol Morphol, 2004. 12:139-141.
  66. Vaiman D. “Genetic Regulation of Recurrent Spontaneous Abortion in Humans”. Biomedical Journal 38.1 (2015): 11-24.
  67. Vassiliadou N. and Bulmer J.N., “Characterization of tubal and decidual leukocyte populations in ectopic pregnancy: evidence that endometrial granulated lymphocytes are absent from the tubal implantation site,” Fertility and Sterility, vol. 69, no. 4, pp. 760–767, 1998.
  68. Ziegler R, Hoover RN, Pike MC, Hildesheim A, Nomura A, et al. (1993): Migration Patterns and Breast Cancer Risks in Asian-American Women. JNCI. 85, 18191827.